Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers

Figueiredo, B. Henriques de; Zacharatou, C.; Galland-Girodet, S.; Benech, J.; Clermont-Gallerande, Henri de; Lamare, F.; Hatt, Mathieu; Digue, Laurence; Pujol, E.; Fernandez, Philippe

doi:10.1007/s00066-014-0752-8

Cited by 36 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Une étude de faisabilité dosimétrique par Servagi-Vernat et al, qui ciblait les zones hypoxiques à partir de trois TEP-Faza (avant radiothérapie, après sept fractions et après 17 fractions), a montré qu'une escalade de dose jusqu'à 86 Gy dans ces zones hypoxiques semblait possible sans modifier significativement la dose délivrée aux organes à risque [75]. Un même type d'étude par Henriques de Figueiredo et al se basait sur des TEP au ( 18 F)-fluoromisonidazole (Miso) avant la radiothérapie et montrait qu'une escalade de dose jusque 79,8 Gy semblait possible dans les zones hypoxiques avec une augmentation de la dose moyenne délivrée aux parotides de l'ordre de 3 Gy [76]. Cependant, il peut exister une variabilité de la distribution spatiale de l'hypoxie d'un jour à l'autre et cette approche reste à ce jour toujours expérimentale [77][78][79].…”

Section: Imagerie Fonctionnelleunclassified

Paramètres de radiorésistance des cancers des voies aérodigestives supérieures et stratégies de radiosensibilisation

Biau

Chautard

Miroir

et al. 2015

Cancer/Radiothérapie

View full text Add to dashboard Cite

Section: Imagerie Fonctionnelleunclassified

Paramètres de radiorésistance des cancers des voies aérodigestives supérieures et stratégies de radiosensibilisation

Biau

Chautard

Miroir

et al. 2015

Cancer/Radiothérapie

View full text Add to dashboard Cite

“…Neben den Anwendungen bei erhöhtem Glukosemetabolismus findet das "Dose Painting" Anwendung in der Hypoxiebildgebung, da in Tumorarealen mit erhöhter Hypoxie eine vermehrte Strahlenresistenz auftritt. In einer kleineren Studie an 10 Patienten führte die [ 18 F]-FMISO-PET-gesteuerte Dosiseskalation zu einer verbesserten Tumorkontrollwahrscheinlichkeit ohne übermäßig gesteigerte Nebenwirkungswahrscheinlichkeit für die Glandula parotidea [16]. Ein weiterer Ansatz ist die wiederholte Bildaufnahme während den Therapiesitzungen.…”

Section: Falsch-positive Pet-befunde Aufgrund Vonunclassified

PET-basierte Bestrahlungsplanung

Grunert¹,

Prasad²

2020

Der Nuklearmediziner

View full text Add to dashboard Cite

Head and neck tumours are associated with high morbidity and mortality. Radiotherapy is an integral part of the treatment of these tumours and [18F]-FDG-PET/CT or PET/MRI is becoming increasingly important in the personalised treatment of head and neck cancer. Advanced tumour stage radiotherapy is combined with chemotherapy and/or surgery. The paper deals with the elementary importance of measuring the exact tumour extent and the resulting determination of the tumour volumes in image-based radiotherapy planning as the basis for successful irradiation. The PET/CT-based target volume definition results in target volume reduction with consecutive protection of risk organs and healthy tissue. Increased glucose metabolism and hypoxic states of cancerous lesions allows PET/CT to correctly identify tumour regions and thereby helps in potential dose escalation for tumour control. PET/MRI shows promising results in the diagnosis of relapses after radiotherapy, but requires further evaluation in larger studies. The [18F]-FDG-PET/CT is ideally suited for therapy evaluation and recurrence diagnosis and has found its way into the ambulatory reimbursement system with some indications due to randomised studies with the highest level of evidence. In addition, the increasing use of machine learning in radiation therapy is emphasised.

show abstract

“…Furthermore, it has been suggested that the role of HIF-1α as a marker of tumour hypoxia may present a significant variability between cell types [19]. Some authors proposed the use of [ 18 F]FMISO in guiding clinical hypoxia-based RT planning as it could provide higher tumour control probability despite a negligible additional radiation boost [20] without remarkable complications for the parotid glands [21]. Lin et al [22], in their study involving seven HNSCC patients, underpinned the applicability of RT planning on the basis of [ 18 F]FMISO distribution.…”

Section: Hypoxiamentioning

confidence: 99%

Non-18F-FDG PET/CT in the management of patients affected by HNC

Quartuccio

Caobelli

Mauro

et al. 2016

Nuclear Medicine Communications

View full text Add to dashboard Cite

PET/computed tomography with F-fluorodeoxyglucose is considered a powerful molecular imaging technique that can provide useful information in the management of patients affected by head and neck cancer. However, misleading findings have been reported because of nonspecific uptake caused by peritumoural inflammation and physiologic changes in nonmalignant tissues in the head and neck region. More specific β-emitting tracers have been introduced that can track other pathological processes. We aimed to review the existing literature performing the search until June 2015 on non-F-fluorodeoxyglucose PET tracers in head and neck cancer to highlight their role in clinical practice.

show abstract

Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers

Abstract: A dose escalation up to 79.8 Gy guided by [(18)F]-FMISO-PET with VMAT seems feasible with improvement of TCP and without excessive increase of NTCP for parotids.

Cited by 36 publications

References 26 publications

Paramètres de radiorésistance des cancers des voies aérodigestives supérieures et stratégies de radiosensibilisation

Paramètres de radiorésistance des cancers des voies aérodigestives supérieures et stratégies de radiosensibilisation

PET-basierte Bestrahlungsplanung

Non-18F-FDG PET/CT in the management of patients affected by HNC

Contact Info

Product

Resources

About